» Articles » PMID: 24682598

Membrane Recruitment of Endogenous LRRK2 Precedes Its Potent Regulation of Autophagy

Overview
Journal Hum Mol Genet
Date 2014 Apr 1
PMID 24682598
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial and idiopathic Parkinson's disease. However, the mechanisms for activating its physiological function are not known, hindering identification of the biological role of endogenous LRRK2. The recent discovery that LRRK2 is highly expressed in cells of the innate immune system and genetic association is a risk factor for autoimmune disorders implies an important role for LRRK2 in pathology outside of the central nervous system. Thus, an examination of endogenous LRRK2 in immune cells could provide insight into the protein's function. Here, we establish that stimulation of specific Toll-like receptors results in a complex biochemical activation of endogenous LRRK2, with early phosphorylation of LRRK2 preceding its dimerization and membrane translocation. Membrane-associated LRRK2 co-localized to autophagosome membranes following either TLR4 stimulation or mTOR inhibition with rapamycin. Silencing of endogenous LRRK2 expression resulted in deficits in the induction of autophagy and clearance of a well-described macroautophagy substrate, demonstrating the critical role of endogenous LRRK2 in regulating autophagy. Inhibition of LRRK2 kinase activity also reduced autophagic degradation and suggested the importance of the kinase domain in the regulation of autophagy. Our results demonstrate a well-orchestrated series of biochemical events involved in the activation of LRRK2 important to its physiological function. With similarities observed across multiple cell types and stimuli, these findings are likely relevant in all cell types that natively express endogenous LRRK2, and provide insights into LRRK2 function and its role in human disease.

Citing Articles

Intramolecular feedback regulation of the LRRK2 Roc G domain by a LRRK2 kinase-dependent mechanism.

Gilsbach B, Ho F, Riebenbauer B, Zhang X, Guaitoli G, Kortholt A Elife. 2024; 12.

PMID: 39699947 PMC: 11658767. DOI: 10.7554/eLife.91083.


Altered Protein Palmitoylation as Disease Mechanism in Neurodegenerative Disorders.

Wlodarczyk J, Bhattacharyya R, Dore K, Ho G, Martin D, Mejias R J Neurosci. 2024; 44(40).

PMID: 39358031 PMC: 11450541. DOI: 10.1523/JNEUROSCI.1225-24.2024.


Lysosomal dysfunction in α-synuclein pathology: molecular mechanisms and therapeutic strategies.

Dai L, Liu M, Ke W, Chen L, Fang X, Zhang Z Cell Mol Life Sci. 2024; 81(1):382.

PMID: 39223418 PMC: 11368888. DOI: 10.1007/s00018-024-05419-5.


How Parkinson's Disease-Linked LRRK2 Mutations Affect Different CNS Cell Types.

Bailey H, Cookson M J Parkinsons Dis. 2024; 14(7):1331-1352.

PMID: 38905056 PMC: 11492021. DOI: 10.3233/JPD-230432.


Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2.

Nazish I, Mamais A, Mallach A, Bettencourt C, Kaganovich A, Warner T Cells. 2024; 13(1).

PMID: 38201257 PMC: 10778119. DOI: 10.3390/cells13010053.


References
1.
Higashi S, Moore D, Yamamoto R, Minegishi M, Sato K, Togo T . Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease. J Neuropathol Exp Neurol. 2009; 68(9):994-1005. PMC: 2768772. DOI: 10.1097/NEN.0b013e3181b44ed8. View

2.
Strisciuglio C, Duijvestein M, Verhaar A, Vos A, van den Brink G, Hommes D . Impaired autophagy leads to abnormal dendritic cell-epithelial cell interactions. J Crohns Colitis. 2012; 7(7):534-41. DOI: 10.1016/j.crohns.2012.08.009. View

3.
Biskup S, Moore D, Celsi F, Higashi S, West A, Andrabi S . Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol. 2006; 60(5):557-569. DOI: 10.1002/ana.21019. View

4.
Choi H, Zhang J, Deng X, Hatcher J, Patricelli M, Zhao Z . Brain Penetrant LRRK2 Inhibitor. ACS Med Chem Lett. 2012; 3(8):658-662. PMC: 3467149. DOI: 10.1021/ml300123a. View

5.
Nichols R, Dzamko N, Morrice N, Campbell D, Deak M, Ordureau A . 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization. Biochem J. 2010; 430(3):393-404. PMC: 2932554. DOI: 10.1042/BJ20100483. View